Inovio Pharmaceuticals Inc (NASDAQ:INO) has been assigned a consensus rating of “Buy” from the seven analysts that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $7.22.
Several research analysts recently weighed in on INO shares. HC Wainwright began coverage on shares of Inovio Pharmaceuticals in a research note on Thursday, May 16th. They issued a “buy” rating and a $13.00 target price for the company. BidaskClub downgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 7th. Zacks Investment Research downgraded shares of Inovio Pharmaceuticals from a “buy” rating to a “hold” rating and set a $3.50 price objective for the company. in a research note on Tuesday, May 28th. Maxim Group reaffirmed a “buy” rating and set a $8.00 price objective on shares of Inovio Pharmaceuticals in a research note on Wednesday, April 3rd. Finally, Cantor Fitzgerald began coverage on shares of Inovio Pharmaceuticals in a research note on Monday, March 25th. They set an “overweight” rating and a $3.62 price objective for the company.
INO stock traded down $0.02 during trading on Monday, hitting $2.47. The stock had a trading volume of 2,820 shares, compared to its average volume of 1,148,887. Inovio Pharmaceuticals has a 1-year low of $2.15 and a 1-year high of $6.30. The company has a market capitalization of $238.22 million, a price-to-earnings ratio of -2.34 and a beta of 1.96. The company has a current ratio of 4.92, a quick ratio of 4.92 and a debt-to-equity ratio of 1.02.
In other news, insider Laurent Humeau bought 20,000 shares of the firm’s stock in a transaction dated Wednesday, June 5th. The stock was acquired at an average price of $2.50 per share, for a total transaction of $50,000.00. Following the acquisition, the insider now owns 45,833 shares of the company’s stock, valued at $114,582.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Jong Joseph Kim sold 500,000 shares of the business’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $2.44, for a total value of $1,220,000.00. Following the sale, the chief executive officer now owns 1,911,055 shares of the company’s stock, valued at approximately $4,662,974.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 2,866,321 shares of company stock valued at $7,055,433. Corporate insiders own 7.90% of the company’s stock.
Several large investors have recently modified their holdings of INO. SG Americas Securities LLC purchased a new position in Inovio Pharmaceuticals in the 1st quarter worth approximately $40,000. Quantamental Technologies LLC purchased a new position in Inovio Pharmaceuticals in the 4th quarter worth approximately $43,000. Amalgamated Bank purchased a new position in Inovio Pharmaceuticals in the 4th quarter worth approximately $50,000. M Holdings Securities Inc. purchased a new position in Inovio Pharmaceuticals in the 1st quarter worth approximately $54,000. Finally, Paloma Partners Management Co boosted its holdings in Inovio Pharmaceuticals by 38.7% in the 4th quarter. Paloma Partners Management Co now owns 16,201 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 4,522 shares during the period. Institutional investors and hedge funds own 47.25% of the company’s stock.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Recommended Story: How Buying a Call Option Works
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.